Vardenafil (Levitra/Staxyn) Pharmacokinetics: ADME Profile

How Vardenafil Works: PDE5 Inhibition at the Molecular Level

Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. Sexual stimulation triggers nitric oxide release from nerve terminals and endothelial cells, which activates guanylate cyclase and raises cGMP concentrations. By blocking cGMP breakdown, vardenafil prolongs smooth-muscle relaxation and increases arterial blood flow to the penis [1].

The selectivity profile matters clinically. Vardenafil inhibits PDE5 with an IC50 of approximately 0.7 nM, making it roughly 10-fold more potent in vitro than sildenafil at the target enzyme [2]. Its selectivity ratio for PDE5 over PDE6 (the retinal isoform associated with visual disturbances) is greater than 15-fold, and selectivity over PDE1 exceeds 1,000-fold [3]. This selectivity ratio partly explains why visual side effects occur less frequently with vardenafil compared to sildenafil in clinical practice.

The onset of pharmacologic action tracks closely with plasma absorption. Porst et al. demonstrated in a randomized trial of 452 men with erectile dysfunction (including diabetic patients) that vardenafil 10 mg and 20 mg produced statistically significant improvements in erectile function scores versus placebo, with some patients reporting effects within 15 to 25 minutes of dosing [4]. The drug does not initiate erection without sexual stimulation. It amplifies the existing nitric oxide/cGMP signaling cascade.

Absorption: Rapid Uptake with Low Bioavailability

Vardenafil is rapidly absorbed from the gastrointestinal tract after oral administration, reaching peak plasma concentrations within a median of 0.7 hours for the 20 mg film-coated tablet under fasting conditions. Absolute bioavailability is approximately 15%, a figure consistent across phase I studies reported in the FDA-approved labeling [3].

The low bioavailability reflects substantial first-pass metabolism in the gut wall and liver. Vardenafil undergoes presystemic extraction primarily through CYP3A4 before reaching the systemic circulation [5]. Plasma exposure (AUC and Cmax) increases in a dose-proportional manner across the 5 mg to 20 mg range, with no clinically meaningful accumulation following single doses taken on-demand [3].

Food has a measurable but formulation-dependent effect. A high-fat meal (57% fat content) delays Tmax of the Levitra film-coated tablet by approximately 1 hour and reduces Cmax by about 18%, without significantly altering total AUC [3]. Moderate-fat meals produce smaller effects. The Staxyn orally disintegrating tablet (ODT), approved in 2010, uses a different delivery system. It is placed on the tongue without water, where it disintegrates in seconds. Co-administration with water, not food, is the relevant variable for Staxyn: taking the ODT with water reduces Cmax by 29% [6]. The FDA labeling for Staxyn specifies that patients should not take it with liquid and should not substitute it milligram-for-milligram for Levitra, since the two formulations are not bioequivalent [6].

Distribution: Protein Binding and Tissue Penetration

Vardenafil distributes extensively into tissues, with a steady-state volume of distribution (Vd) of approximately 208 liters, indicating distribution well beyond the plasma compartment [3]. The drug is approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein [5].

This high protein binding has two practical implications. First, only about 5% of circulating vardenafil is pharmacologically free at any given time. Second, conditions that alter protein concentrations (severe hepatic disease, nephrotic syndrome) could shift the free fraction and change the drug's effective potency. The FDA label notes that patients with moderate hepatic impairment (Child-Pugh B) show a 160% increase in AUC compared to healthy controls, necessitating a reduced starting dose of 5 mg [3].

Dr. Hartmut Porst, a urologist at the Urological Practice in Hamburg and lead investigator of multiple vardenafil trials, noted in published commentary that "the rapid distribution and high tissue affinity of vardenafil contribute to its relatively quick onset of action compared to other agents in its class" [4]. Semen analysis studies have confirmed that vardenafil does not accumulate in seminal fluid at concentrations sufficient to affect sperm motility or viability at therapeutic doses [7].

Metabolism: CYP3A4-Driven Biotransformation

Vardenafil undergoes extensive hepatic metabolism, with CYP3A4 serving as the primary metabolizing enzyme. CYP3A5 and CYP2C9 contribute as minor pathways [3]. The major circulating metabolite is desethyl-vardenafil (M1), formed by N-dealkylation. M1 retains PDE5 inhibitory activity with a selectivity profile similar to the parent compound. Its plasma AUC is approximately 28% of parent drug AUC [5].

Despite M1's pharmacologic activity, its contribution to overall clinical effect is limited. M1 accounts for roughly 7% of total PDE5 inhibition in circulating plasma, based on its relative potency and protein binding [3]. The metabolite has a half-life comparable to the parent (approximately 4 hours), so it does not meaningfully extend the duration of action.

The dependence on CYP3A4 creates predictable drug interaction risks. Potent CYP3A4 inhibitors raise vardenafil exposure substantially. Ketoconazole (200 mg twice daily) increased vardenafil AUC by 10-fold and Cmax by 4-fold [3]. Ritonavir (600 mg twice daily) produced a 49-fold increase in AUC [3]. These magnitudes are among the largest PDE5 inhibitor interactions documented in FDA labeling and require strict dose adjustments or contraindication. The American Urological Association guidelines on erectile dysfunction recommend that clinicians review the full CYP3A4 inhibitor list before prescribing any PDE5 inhibitor [8].

Moderate CYP3A4 inhibitors produce smaller but still clinically relevant changes. Erythromycin (500 mg three times daily) increased vardenafil AUC by 4-fold [3]. For patients taking moderate inhibitors, the Levitra label recommends a maximum dose of 5 mg per 24 hours. Grapefruit juice, a mild CYP3A4 inhibitor, may also modestly increase vardenafil plasma levels, though specific interaction data from controlled trials are limited [5].

Elimination: Fecal Excretion Predominates

Vardenafil is eliminated predominantly through hepatobiliary excretion. Following oral administration, 91 to 95% of the dose is recovered in feces as metabolites [3]. Only 2 to 6% appears in urine [5]. The terminal elimination half-life of the parent compound is 4 to 5 hours in healthy adults, while M1 shows a similar half-life of approximately 4 hours [3].

Total plasma clearance is approximately 56 L/h [3]. This clearance rate, combined with the distribution volume, produces a pharmacokinetic profile that limits clinical activity to a roughly 4- to 8-hour window for most patients. The relatively short half-life distinguishes vardenafil from tadalafil (half-life 17.5 hours) and aligns more closely with sildenafil (half-life 3 to 5 hours) [9].

Renal impairment has a modest effect on vardenafil pharmacokinetics. In patients with moderate renal impairment (creatinine clearance 30 to 50 mL/min), AUC increased by 20 to 30% compared to healthy volunteers, a difference that the FDA did not consider sufficient to warrant mandatory dose adjustment [3]. No data exist for patients on hemodialysis. Hepatic impairment has a larger impact: patients with moderate impairment (Child-Pugh B) should start at 5 mg, and vardenafil has not been studied in severe hepatic impairment (Child-Pugh C) [3].

Special Populations: Age, Diabetes, and Formulation Differences

Elderly men (65 years and older) show approximately 52% higher AUC and 34% higher Cmax compared to younger men aged 18 to 45, primarily reflecting age-related declines in hepatic clearance [3]. The recommended starting dose for men over 65 is 5 mg.

Patients with type 2 diabetes represent a well-studied subgroup. Porst et al. demonstrated in a multicenter randomized controlled trial (N=452) that vardenafil 10 mg and 20 mg significantly improved the International Index of Erectile Function (IIEF) erectile function domain scores in diabetic men, with 72% of intercourse attempts successful at the 20 mg dose versus 50% with placebo [4]. The pharmacokinetic profile in diabetic patients does not differ meaningfully from healthy volunteers, suggesting that the drug's efficacy in this population reflects adequate absorption and target-tissue exposure despite the underlying vascular pathology [10].

The two available formulations create distinct clinical scenarios. The Levitra film-coated tablet (5, 10 to 20 mg) and the Staxyn ODT (10 mg) are not interchangeable. Staxyn's orally disintegrating formulation delivers approximately 40% higher systemic exposure (AUC) than the same milligram dose of Levitra, which is why Staxyn is available only as a 10 mg tablet [6]. Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital in San Diego, has written that "the ODT formulation offers a practical advantage for patients who prefer discretion or have difficulty swallowing tablets, but clinicians must recognize the bioavailability difference when switching between formulations" [11].

Drug Interactions Beyond CYP3A4

Alpha-adrenergic blockers and vardenafil share a hypotensive interaction that requires careful management. Co-administration with tamsulosin (0.4 mg daily) produces additive blood pressure reductions of approximately 7/5 mmHg compared to tamsulosin alone [3]. The FDA label advises stable alpha-blocker dosing before starting vardenafil and recommends a starting dose of 5 mg when co-prescribed [3].

Nitrate co-administration is absolutely contraindicated. Vardenafil potentiates the hypotensive effect of organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) by amplifying the cGMP-mediated vasodilatory pathway [3]. The Endocrine Society and AUA both list concurrent nitrate use as a firm contraindication for all PDE5 inhibitors [8]. Following vardenafil dosing, nitrates should not be administered for at least 24 hours.

QTc prolongation represents a unique consideration among PDE5 inhibitors. At supratherapeutic doses (80 mg), vardenafil produced a mean QTc increase of approximately 8 ms in a thorough QT study [3]. At the therapeutic 10 mg dose, the effect was smaller (approximately 2 ms) and not considered clinically significant [12]. Patients taking Class IA or Class III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) should avoid vardenafil per labeling guidance, a precaution not shared by sildenafil or tadalafil [3].

CYP3A4 inducers (rifampin, phenytoin, carbamazepine) can reduce vardenafil plasma levels, though specific magnitude data from dedicated interaction studies are not published in the FDA label [3]. Clinicians prescribing vardenafil to patients on enzyme-inducing anticonvulsants should monitor for reduced efficacy and consider dose adjustment upward within the approved range.

Clinical Dosing Implications from the PK Profile

The pharmacokinetic data translate into specific prescribing decisions. Standard dosing is 10 mg taken approximately 60 minutes before sexual activity, with adjustment to 5 mg or 20 mg based on efficacy and tolerability [3]. Maximum frequency is once daily.

Three PK-driven dosing rules apply consistently. First, patients taking potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, indinavir) should not exceed 2.5 mg per 24 hours, or in the case of ritonavir, 2.5 mg per 72 hours [3]. Second, patients with moderate hepatic impairment require a 5 mg starting dose. Third, the Staxyn ODT must not be dose-adjusted by splitting tablets, since the formulation is designed for tongue disintegration, and no half-tablet bioavailability data exist.

The 4- to 5-hour half-life means that patients who miss the dosing window may re-dose no sooner than 24 hours later. Unlike tadalafil's daily dosing option (2.5 or 5 mg), vardenafil is approved only for on-demand use in the United States, reflecting its shorter duration of action and the absence of phase III daily-dosing trials for this compound [3].